OriCell Therapeutics Holdings Limited (operating as OriCell Therapeutics Co., Ltd.) is a clinical-stage biotechnology company headquartered in Shanghai, China, with operations expanding internationally including in the United States. Founded in 2015, the company specializes in the research, development, and global commercialization of novel cell therapies and immunotherapies. OriCell focuses on addressing significant unmet medical needs in oncology and immunology, with a particular strategic emphasis on breaking through the historic barriers of chimeric antigen receptor T-cell (CAR-T) therapies in solid tumors, as well as hematologic malignancies.
The organization relies on an integrated "Platform and Pipeline" business model that combines proprietary antibody discovery engines, T-cell armoring technologies, and rapid biomanufacturing capabilities to deliver durable and cost-effective cellular medicines to the global patient community.
Proprietary Technology Triad
OriCell's therapeutic design and development pipeline is powered by three core platform technologies:
OriAb (Antibody Discovery Platform): A target screening and antibody engineering platform featuring a human naive phage-display library ($10^{11}$ diversity) and a synthetic nanobody library ($10^{11}$ diversity). It is optimized to identify novel binding domains and high-affinity single-chain variable fragments (scFvs) specifically tailored for CAR-T construct architecture.
OriArmoring (Functional Enhancement Platform): A proprietary T-cell armoring technology engineered to overcome the hostile, immunosuppressive tumor microenvironment (TME) in solid tumors. Constructs engineered with OriArmoring promote a higher ratio of memory T cells, increase intratumoral infiltration, resist T-cell exhaustion, and boost anti-tumor durability.
OnGo CMC (Rapid Manufacturing Platform): A specialized cell processing and contract development/manufacturing platform designed to optimize stemness-based CAR-T manufacturing. The process drastically reduces autologous manufacturing turnaround times, improving cell product yield and viability.
Key Pipeline Assets and Clinical Programs
OriCell is advancing a diversified portfolio of autologous, allogeneic, rapid-production, and next-generation in vivo CAR-T programs through clinical development:
Overview: OriCell's lead clinical-stage solid tumor asset. Ori-C101 targets Glypican-3 (GPC3), a surface antigen overexpressed in liver cancer cells. It has cleared investigational new drug (IND) applications with both the National Medical Products Administration (NMPA) in China and the U.S. FDA, demonstrating high objective response rates (ORR) and manageable safety profiles across Phase I and investigator-initiated trials as it advances toward pivotal clinical evaluation.
2. OriCAR-017 (GPRC5D-Targeted CAR-T)
Indication: Relapsed or Refractory Multiple Myeloma (r/r MM).
Overview: An autologous CAR-T therapy targeting G-protein-coupled receptor class C group 5 member D (GPRC5D). OriCAR-017 has received U.S. FDA IND clearance, FDA Orphan Drug Designation (ODD), and FDA Fast Track Designation. Clinical data published in publications such as The Lancet Haematology highlight deep treatment responses in patients previously refractory to conventional therapies or prior BCMA-targeted treatments.
3. Advanced & Next-Generation Programs
OriC613 & Dual-Targeting CAR-Ts: Pipeline candidates focused on bispecific constructs (such as BCMA × GPRC5D CAR-T) engineered to prevent antigen escape in hematologic malignancies.
Secreted & In Vivo CAR-T Technologies: Preclinical and early-stage platforms researching targeted in vivo viral and non-viral vector delivery mechanisms to generate CAR-T cells directly within the patient body, eliminating the need for complex ex vivo autologous manufacturing workflows.
Please note: This information is generated by AI. For legal use, verify with company sources.
